Hyaluronic Acid Filler IMD1 Basic for Correction of Nasolabial Folds

Volunteers receive one injection IMD1 basic of correction of nasolabial folds and are followed-up for up to 36 weeks.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Nasolabial Folds

Age range

30 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Merz Pharmaceuticals

Frankfurt, 60318, Germany

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

main inclusion criteria: severity rating scale grade 3 or 4

Exclusion criteria

main exclusion criterion: other nasolabial fold corrections within 6 months prior to study entry

Treatment and study plan

Hyaluronic acid filler/IMD1 basic

Drug

Primary outcomes

Severity rating scale assessed by independent rater

Sponsors and collaborators

Lead sponsor

Merz Pharmaceuticals GmbH

Industry

Registry information

Official study title

Prospective, Multicentre, Not Controlled Clinical Study to Investigate Efficacy and Tolerability of the Hyaluronic Acid Filler IMD1 Basic After Single Bilateral Injection for Correction of Nasolabial Folds (NLF)

Important dates

Study start: 2005
Study completion: 2006
First posted: Jan 31, 2007
Registry last updated: Feb 7, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed